Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palm Oil Enriched With Plant Sterols
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Institut Pertanian Bogor
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palm Oil Enriched With Plant Sterols is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperlipidemias.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Palm Oil Enriched With Plant Sterols
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Institut Pertanian Bogor
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CLA-Fortified Milk
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Recipient : Indonesia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Conjugated Linoleic Acid on Body Weight and Body Fat Mass for 12 Weeks
Details : CLA-Fortified Milk is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : CLA-Fortified Milk
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Recipient : Indonesia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hepaxa
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hepaxa Management of Non-alcoholic Fatty Liver Disease
Details : Hepaxa is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 11, 2019
Lead Product(s) : Hepaxa
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olive
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Olive
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Sleep
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2018
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Sleep
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2017
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linoleic Acid
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
CLA and Vitamin D on Protein Turnover
Details : Linoleic Acid is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 14, 2017
Lead Product(s) : Linoleic Acid
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients
Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 05, 2016
Lead Product(s) : Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pronovapure
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood
Details : Pronovapure is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 05, 2016
Lead Product(s) : Pronovapure
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omega-3
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Plasma Diurnal Variation in and Absorption of EPA and DHA
Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Fetal Nutrition Disorders.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 22, 2016
Lead Product(s) : Omega-3
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Recipient : Northumbria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
